Voleon Capital Management LP Takes Position in Medpace Holdings, Inc. $MEDP

Key Points

• Voleon Capital Management LP acquired a new stake in Medpace Holdings, Inc., purchasing 4,198 shares valued at approximately $1.279 million in the first quarter.
• Multiple institutional investors significantly increased their holdings in Medpace, with Jacobs Levy Equity Management raising its position by 675.8%, now owning 121,464 shares valued at $37 million.
• Analysts' ratings for Medpace are mixed, with two Buy ratings, eleven Hold ratings, and three Sell ratings, while the consensus price target stands at $412.73.

Voleon Capital Management LP acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,198 shares of the company's stock, valued at approximately $1,279,000.

A number of other institutional investors have also modified their holdings of the company. Dynamic Technology Lab Private Ltd raised its position in shares of Medpace by 397.0% in the first quarter. Dynamic Technology Lab Private Ltd now owns 4,080 shares of the company's stock valued at $1,243,000 after buying an additional 3,259 shares during the last quarter. Scientech Research LLC raised its position in shares of Medpace by 115.4% in the first quarter. Scientech Research LLC now owns 3,043 shares of the company's stock valued at $927,000 after buying an additional 1,630 shares during the last quarter. Petrus Trust Company LTA acquired a new position in shares of Medpace in the first quarter valued at approximately $203,000. NewEdge Advisors LLC raised its position in shares of Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company's stock valued at $319,000 after buying an additional 190 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in shares of Medpace by 675.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company's stock valued at $37,009,000 after buying an additional 105,807 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Truist Financial boosted their price objective on shares of Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Cowen downgraded shares of Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Rothschild Redb downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, September 3rd. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Finally, Rothschild & Co Redburn downgraded shares of Medpace from a "buy" rating to a "neutral" rating and boosted their target price for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Two analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Reduce" and a consensus price target of $412.73.

Medpace Stock Up 1.0%

MEDP opened at $492.09 on Tuesday. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $501.30. The company has a 50 day moving average of $416.25 and a two-hundred day moving average of $345.24. The company has a market cap of $13.82 billion, a P/E ratio of 36.59, a P/E/G ratio of 3.06 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. During the same period in the previous year, the firm earned $2.75 earnings per share. Medpace's revenue for the quarter was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 36,196 shares of the business's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the completion of the sale, the chief executive officer directly owned 925,799 shares in the company, valued at $440,587,744.10. The trade was a 3.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kevin M. Brady sold 12,000 shares of the company's stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the completion of the transaction, the chief financial officer owned 6,000 shares of the company's stock, valued at $2,725,380. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock valued at $74,111,427 over the last quarter. Company insiders own 20.30% of the company's stock.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.